Identification of novel therapeutic targets in acute leukemias with NRAS mutations using a pharmacologic approach

Blood

Volumn 125, Issue 20, 2015, Pages 3133-3143

  Nonami, Atsushi ^a   Sattler, Martin ^a   Weisberg, Ellen ^a   Liu, Qingsong ^b   Zhang, Jianming ^b   Patricelli, Matthew P ^c   Christie, Amanda L ^a   Saur, Amy M ^a   Kohl, Nancy E ^a   Kung, Andrew L ^a   Yoon, Hojong ^d   Sim, Taebo ^a,d   Gray, Nathanael S ^b   Griffin, James D ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c ACTIVX BIOSCIENCES INC   (United States)

^d Korea Institute of Science and Technology   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE 2; N [4 METHYL 3 [1 METHYL 7 (6 METHYLPYRIDIN 3 YLAMINO) 2 OXO 1,2 DIHYDROPYRIMIDOL [4,5]PYRIMIDIN 3(4H) YL PHENYL] 3 (TRIFLUOROMETHYL)BENZAMIDE; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN KINASE B; RECEPTOR FOR ACTIVATED C KINASE 1; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; FUSED HETEROCYCLIC RINGS; GERMINAL CENTER KINASES; GUANOSINE TRIPHOSPHATASE; MEMBRANE PROTEIN; MOLECULAR LIBRARY; N-(4-METHYL-3-(1-METHYL-7-(6-METHYLPYRIDIN-3-YLAMINO)-2-OXO-1,2-DIHYDROPYRIMIDO(4,5-D)PYRIMIDIN-3(4H)-YL)PHENYL)-3-(TRIFLUOROMETHYL)BENZAMIDE; NRAS PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; PROTEIN SERINE THREONINE KINASE; PYRIMIDINONE DERIVATIVE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG INHIBITION; DRUG POTENCY; DRUG SELECTIVITY; DRUG TARGETING; GENE MUTATION; GENE TARGETING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; ONCOGENE N RAS; PRIORITY JOURNAL; ANIMAL; ANTAGONISTS AND INHIBITORS; APOPTOSIS; CELL CYCLE CHECKPOINT; DISEASE MODEL; DRUG EFFECTS; DRUG SCREENING; GENETICS; LEUKEMIA; METABOLISM; MOLECULAR LIBRARY; MORTALITY; MUTATION; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BICYCLO COMPOUNDS, HETEROCYCLIC; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; DRUG SCREENING ASSAYS, ANTITUMOR; GTP PHOSPHOHYDROLASES; HUMANS; LEUKEMIA; MEMBRANE PROTEINS; MICE; MUTATION; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS C-AKT; PYRIMIDINONES; SIGNAL TRANSDUCTION; SMALL MOLECULE LIBRARIES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84946770965     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-12-615906     Document Type: Article

References (32)

1. Diaz-Flores E, Shannon K. Targeting oncogenic Ras. Genes Dev. 2007;21(16):1989-1992.
2. Karp JE, Lancet JE, Kaufmann SH, et al. Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinicallaboratory correlative trial. Blood. 2001;97(11): 3361-3369.
3. Ostrem JM, Peters U, Sos ML, Wells JA, Shokat KM. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature. 2013;503(7477):548-551.
4. Hatzivassiliou G, Song K, Yen I, et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature. 2010;464(7287):431-435.
5. Jain N, Curran E, Iyengar NM, et al. Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial. Clin Cancer Res. 2014;20(2):490-498.
6. Barbie DA, Tamayo P, Boehm JS, et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1.Nature. 2009;462(7269):108-112.
7. Scholl C, Fröhling S, Dunn IF, et al. Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell. 2009;137(5):821-834.
8. Kumar MS, Hancock DC, Molina-Arcas M, et al. The GATA2 transcriptional network is requisite for RAS oncogene-driven non-small cell lung cancer. Cell. 2012;149(3):642-655.
9. Kaelin WG Jr. The concept of synthetic lethality in the context of anticancer therapy. Nat Rev Cancer. 2005;5(9):689-698.
10. Babij C, Zhang Y, Kurzeja RJ, et al. STK33 kinase activity is nonessential in KRAS-dependent cancer cells. Cancer Res. 2011;71(17): 5818-5826.
11. Luo T, Masson K, Jaffe JD, et al. STK33 kinase inhibitor BRD-8899 has no effect on KRASdependent cancer cell viability. Proc Natl Acad Sci USA. 2012;109(8):2860-2865.
12. Choi HG, Ren P, Adrian F, et al. A type-II kinase inhibitor capable of inhibiting the T315I"gatekeeper" mutant of Bcr-Abl. J Med Chem. 2010;53(15):5439-5448.
13. Patricelli MP, Szardenings AK, Liyanage M, et al. Functional interrogation of the kinome using nucleotide acyl phosphates. Biochemistry. 2007; 46(2):350-358.
14. Anastassiadis T, Deacon SW, Devarajan K, Ma H, Peterson JR. Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity. Nat Biotechnol. 2011;29(11): 1039-1045.
15. Warmuth M, Kim S, Gu XJ, Xia G, Adrián F. Ba/F3 cells and their use in kinase drug discovery. Curr Opin Oncol. 2007;19(1):55-60.
16. Kwong LN, Costello JC, Liu H, et al. Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma. Nat Med. 2012; 18(10):1503-1510.
17. Guo T, Agaram NP, Wong GC, et al. Sorafenib inhibits the imatinib-resistant KITT670I gatekeeper mutation in gastrointestinal stromal tumor. Clin Cancer Res. 2007;13(16):4874-4881.
18. Sanda T, Tyner JW, Gutierrez A, et al. TYK2-STAT1-BCL2 pathway dependence in T-cell acute lymphoblastic leukemia. Cancer Discov. 2013;3(5):564-577.
19. Huang W, Erikson RL. Constitutive activation of Mek1 by mutation of serine phosphorylation sites. Proc Natl Acad Sci USA. 1994;91(19):8960-8963.
20. Hirai H, Sootome H, Nakatsuru Y, et al. MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Mol Cancer Ther. 2010;9(7):1956-1967.
21. Mahajan K, Mahajan NP. PI3K-independent AKT activation in cancers: a treasure trove for novel therapeutics. J Cell Physiol. 2012;227(9): 3178-3184.
22. Mahajan K, Coppola D, Rawal B, et al. Ack1-mediated androgen receptor phosphorylation modulates radiation resistance in castrationresistant prostate cancer. J Biol Chem. 2012; 287(26):22112-22122.
23. Dzamko N, Inesta-Vaquera F, Zhang J, et al. The IkappaB kinase family phosphorylates the Parkinson's disease kinase LRRK2 at Ser935 and Ser910 during Toll-like receptor signaling. PLoS ONE. 2012;7(6):e39132.
24. Balzano D, Santaguida S, Musacchio A, Villa F. A general framework for inhibitor resistance in protein kinases. Chem Biol. 2011;18(8): 966-975.
25. Chadee DN, Yuasa T, Kyriakis JM. Direct activation of mitogen-activated protein kinase kinase kinase MEKK1 by the Ste20p homologue GCK and the adapter protein TRAF2. Mol Cell Biol. 2002;22(3):737-749.
26. Dar AC, Das TK, Shokat KM, Cagan RL. Chemical genetic discovery of targets and antitargets for cancer polypharmacology. Nature. 2012;486(7401):80-84.
27. Knight ZA, Lin H, Shokat KM. Targeting the cancer kinome through polypharmacology. Nat Rev Cancer. 2010;10(2):130-137.
28. Nur-E-Kamal A, Zhang A, Keenan SM, et al. Requirement of activated Cdc42-associated kinase for survival of v-Ras-transformed mammalian cells. Mol Cancer Res. 2005;3(5): 297-305.
29. Pombo CM, Kehrl JH, Sánchez I, et al. Activation of the SAPK pathway by the human STE20 homologue germinal centre kinase. Nature. 1995; 377(6551):750-754.
30. Katz P, Whalen G, Kehrl JH. Differential expression of a novel protein kinase in human B lymphocytes. Preferential localization in the germinal center. J Biol Chem. 1994;269(24): 16802-16809.
31. Yuasa T, Ohno S, Kehrl JH, Kyriakis JM. Tumor necrosis factor signaling to stress-activated protein kinase (SAPK)/Jun NH2-terminal kinase (JNK) and p38. Germinal center kinase couples TRAF2 to mitogen-activated protein kinase/ERK kinase kinase 1 and SAPK while receptor interacting protein associates with a mitogenactivated protein kinase kinase kinase upstream of MKK6 and p38. J Biol Chem. 1998;273(35): 22681-22692.
32. Cellurale C, Sabio G, Kennedy NJ, et al. Requirement of c-Jun NH(2)-terminal kinase for Ras-initiated tumor formation. Mol Cell Biol. 2011; 31(7):1565-1576.